



PCT/EP 03 / 07 6 03

REQU 19 AOUT 2003
OMI. PCT



INVESTOR IN PEOPLE

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



R. Mahoney

Signed

Dated 17 April 2003



The
**Patent
Office**

1/77
15 OCT 02 E75969-1 D0524
P0157700 0.00-0223974.7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1.	Your reference	G-32502P1/ABR 9921		
2.	Patent application number (The Patent Office will fill in this part)	0223974.7		15 OCT 2002
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	BIOCHEMIE GBESELLSCHAFT MBH A-6250 KUNDL TIROL AUSTRIA		
	Patent ADP number (if you know it)	8355158001		
	If the applicant is a corporate body, give the country/state of its incorporation	AUSTRIA		
4.	Title of invention	Organic compounds		
5.	Name of your agent (if you have one)	B.A. YORKE & CO.		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	CHARTERED PATENT AGENTS COOMB HOUSE, 7 ST. JOHN'S ROAD ISLEWORTH MIDDLESEX TW7 6NH		
	Patents ADP number (if you know it)	1800001		
6.	If you are declaring priority from one ore more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
	a) any applicant named in part 3 is not an inventor, or			
	b) there is an inventor who is not named as an applicant, or			
	c) any named applicant is a corporate body.			
	(see note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 8 ✓

Claim(s) 2 ✓

Abstract 1 ✓

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

One ✓

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co.

B.A. Yorke & Co.

15 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham
020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

- 1 -

Organic compounds

The present invention relates to organic compounds e.g. antimicrobial compounds such as cephalosporins.

- 5 In one aspect the present invention provides a compound of formula



wherein

W is CH or N,

R₁ is hydrogen or O-R₁,

- 10 R₁ is hydrogen, (C₁₋₆)alkyl, halo(C₁₋₆)alkyl or hydroxycarbonyl(C₁₋₆)alkyl,

R₂ is hydrogen or an ester moiety,

R₃ is hydrogen, (C₁₋₂)alkyl, allyl or (C₃₋₈)cycloalkyl,

R₄ is hydrogen or (C₁₋₂)alkyl,

- 15 R₅ and R₆ independently of each other are hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl-carbonyloxy, arylcarbonyloxy, (C₁₋₆)alkylsulfonyl or arylsulfonyl, and

X = NH, O or S.

N-R₅R₆ can be in o, m or p position.

In a preferred aspect the present invention provides a compound of formula I wherein

- 20 R₁ is fluoromethyl

R₂, R₄, R₅ and R₆ are hydrogen,

R₃ is methyl,

X = NH, and

N-R₅R₆ is in m position.

25

An ester moiety includes alkyl; e.g. unsubstituted alkyl or substituted alkyl, e.g. by aryl, such as benzyl, alkoxybenzyl, such as 4-methoxybenzyl, alkoxy, such as methoxymethyl; alkyloxycarbonyloxy; alkyl; alkoxy, such as glycyloxy, phenylglycyloxy, e.g. glycyloxymethyl, phenylglycyloxymethyl; heterocyclyl e.g. 5-methyl-2-oxo-1,3-dioxolen-4-yl;

indanyl, phthalidyl, alkoxycarbonyloxy and ester moieties which form with the COO^- group a physiologically hydrolysable and acceptable ester, e.g. such known to be hydrolysable ester groups in the field of cephalosporins. A compound of formula I may thus be in the form of an physiologically-hydrolysable and -acceptable ester. By physiologically-hydrolysable and -

5 acceptable esters as used herein is meant an ester in which the COO^- group is esterified and which is hydrolysable under physiological conditions to yield an acid which is itself physiologically tolerable at dosages to be administered. The term is thus to be understood as defining regular pro-drug forms. An ester moiety may be preferably a group which is easily hydrolysable under physiological conditions. Such esters may be administered
10 preferably orally. Parenteral administration may be indicated if the ester *per se* is an active compound or, if hydrolysis occurs in the blood.

If not otherwise indicated herein any carbon containing group may contain up to 20 carbon atoms. Aryl includes (C_{6-18}) aryl, preferably phenyl, naphthyl, e.g. phenyl.


15 Any group(s) may be unsubstituted or one or morefold substituted, e.g. substituted by groups as conventional in cephalosporin chemistry.

In this specification unless otherwise indicated terms such as "compound of formula I" embrace the compound in any form, for example in the form of a salt and in free base form. The present invention thus includes a compound in free base form or, e.g. where such forms exist, in the form of a salt, for example in the form of an acid addition salt, inner salt, quaternary salt and/or in the form of a solvate, for example in the form of a hydrate. A salt may be a pharmaceutically acceptable salt of a compound of formula I such as a metal salt
25 or an amine salt. Metal salts include for example sodium, potassium, calcium, barium, zinc, aluminum salts, preferably sodium or potassium salts. Amine salts include for example trialkylamine, procaine, dibenzylamine and benzylamine salts. The amino group of the cyclohexyl ring in a compound of formula I may be e.g. a NH_3^+ group, $\text{NR}_5\text{R}_6\text{R}_7^+$, NHR_5R_6 or NH_2R_5 , wherein R_5 and R_6 have the before said meanings and R_7 independently of R_5 and R_6
30 may have the same meaning as those. Counterions are those as conventional, e.g. hydroxy or chloride ions. A free form of a compound of formula I may be converted into a salt form, a solvate form or a salt and a solvate form and *vice versa*.


- 3 -

In a further aspect the present invention provides a compound of formula I in the form of a salt, for example an acid addition salt or a metal salt; e.g. and a compound of formula I in free form, in the form of a salt, in the form of a solvate or in the form of a salt and a solvate.

- 5 The present invention includes a compound of formula I in any isomeric/tautomeric form in which it may exist. E.g. the configuration in group



may (co)exist in the form of




- 10 Also e.g. geometric isomers if R_1 is other than hydrogen may be syn [(Z)] and anti [(E)] and is preferably syn [(Z)]. E.g. a chiral carbon atom may be introduced, e.g. during a production process of a compound of formula I and corresponding stereoisomeric forms of a compound of formula I may be obtained, e.g. a mixture of the individual stereoisomers, e.g. a racemate, or pure isostereoisomeric forms. Mixtures of isomers may be separated according to a
15 method as conventional.

The present invention includes a compound of formula I in any tautomeric form, in any isomeric mixtures and in the form of pure isomers.


- Any compound mentioned herein, e.g. a compound of the present invention, may be
20 prepared as appropriate, e.g. analogously to a method as conventional or as disclosed herein.

In another aspect the present invention provides a process for the production of a compound of formula I by reacting a compound of formula



- 4 -

wherein R_1 and R_2 are defined as described before, with a compound of formula



wherein R_3 , R_4 , R_5 and R_6 are defined as described before.

- 5 If desired, reactive groups may be protected with protecting groups, which may be, or, which are split off under the reaction conditions, or after the reaction. A compound of formula I wherein R_2 is hydrogen may be converted into a compound of formula I wherein R_2 is an carboxylic acid ester group. A compound of formula I may be isolated from the reaction mixture as appropriate, e.g. analogously to a method as conventional.

- 10 The compounds of formula I e.g. including salt/solvate, hereinafter designated as "active compound(s) of the invention" exhibit pharmacological activity, e.g. beside low toxicity and are therefore useful as pharmaceuticals. In particular, the active compounds of the invention show antimicrobial, e.g. antibacterial, activity against e.g. gram negative and gram positive
- 15 bacteria, e.g. gram positive bacteria, such as e.g. Escherichia, e.g. Escherichia coli; Enterobacter, e.g. Enterobacter cloacae; Enterococcus, e.g. Enterococcus faecalis; Klebsiella, e.g. Klebsiella pneumoniae; Streptococcus, e.g. Streptococcus pneumoniae; Staphylococcus, e.g. Staphylococcus aureus; and Pseudomonas, e.g. Pseudomonas aeruginosa, in vitro in the Agar Dilution Test according to National Committee for Clinical
- 20 Laboratory Standards (NCCLS) 1993, Document M7-A3Vol.13, No. 25: "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition, Approved Standard". The active compounds show an MIC ($\mu\text{g/ml}$) in the Agar Dilution Test from about <0.0125 to ca. >6.25. The active compounds of the invention show a surprising overall activity spectrum. The activities for a salt form and/or a solvate form of the compound of
- 25 formula I are in the same range as the activity of the compound of formula I in free form.

In another aspect the present invention provides an active compound for use as a pharmaceutical, preferably as an antimicrobial agent, such as an antibiotic.

- 30 In a further aspect the present invention provides an active compound of the present invention for use in the preparation of a medicament for the treatment of microbial diseases,

for example diseases mediated by bacterias selected from *Escherichia*, *Enterobacter*, *Enterococcus*, *Klebsiella*, *Streptococcus*, *Staphylococcus* and *Pseudomonas*.

The present invention provides in further aspects

- 5 - an active compound of the present invention for use as a pharmaceutical in the treatment of microbial diseases caused by bacterias selected from *Escherichia*, *Enterobacter*, *Enterococcus*, *Klebsiella*, *Streptococcus*, *Staphylococcus* and *Pseudomonas*; and
- the use of an active compound of the present invention or the use of a pharmaceutical composition comprising an active compound of the present invention as a pharmaceutical.

- 10 In a further aspect the present invention provides a method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of an active compound of the present invention.

Treatment includes disease treatment as well as prophylactic treatment.

- 15 For this indication, the appropriate dosage will, of course, vary depending upon, for example, the compound of formula I used, the host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.05 to 5 g, for example 0.1 to about 2.5 g, of an active compound of the invention conveniently
- 20 administered, for example, in divided doses up to four times a day.

An active compound of the invention may be administered by any conventional route, for example orally, e.g. in form of tablets or capsules, or parenterally in the form of injectable solutions or suspensions, e.g. in analogous manner to ceftazidime.

- 25 The compound of example 1 is a preferred compound of the present invention. It has, for example been determined that the MIC ($\mu\text{g/ml}$) of the compound of Example 1 against, for example *Klebsiella pneumoniae* is about 0.0125. It is therefore, indicated that for the treatment of microbial diseases, e.g. bacterial diseases, the preferred compounds of the invention may be administered to larger mammals, for example humans, by similar modes of
- 30 administration at similar dosages than conventionally used with ceftazidime.

The compounds of formula I may be administered in pharmaceutically acceptable salt form, e.g. acid addition salt form or base addition salt form or in the corresponding free forms, optionally in solvate form. Such salts exhibit the same order of activity as the free forms.

- 6 -

In another aspect the present invention provides a pharmaceutical composition comprising an active compound of the present invention in association with at least one pharmaceutically excipient. Such compositions may be manufactured accordingly, e.g.
5 analogously to a method as conventional. Pharmaceutical excipient(s) include(s) pharmaceutically active excipient.

In the following examples which illustrate the present invention all temperatures are given in degree centigrade. RT means room temperature.

10

EXAMPLE 1**A) SYNTHESIS OF INTERMEDIATE COMPOUNDS****a) Benzyldiene derivative of 3-amino-1-(3-(aminobenzylamino)-3-methyl-guanidine in the form of a monohydrochloride**

5 35 g of the benzyldiene derivative of S-methyl-2-methyl-isothiosemicarbazide in the form of a hydrochloride and 32.79 g of 3-aminobenzol in 300 ml of MeOH are refluxed. The mixture obtained is stirred at RT, a precipitate forms, is filtered off and solvent is evaporated. The evaporated residue is treated with 217.5 ml of 2M HCl, a precipitate formed is filtered off, washed and dried. The volume of the filtrate obtained is brought to about 150 ml, a
 10 precipitate is formed, filtered off, washed and dried. The dried, combined precipitates are recrystallized from water and the benzyldiene derivative of 3-amino-1-(3-(aminobenzylamino)-3-methyl-guanidine in the form of a monohydrochloride is obtained.

b) 3-amino-1-(3-(aminobenzylamino)-3-methyl-guanidine dihydrochloride

From a mixture of 24.74 g of the benzyldiene derivative of 3-amino-1-(3-(aminobenzyl-
 15 amino)-3-methyl-guanidine in the form of a monohydrochloride in 79.9 ml of 2M HCl, benzaldehyde is distilled off and solvent from the remaining mixture is evaporated. 3-amino-1-(3-(aminobenzylamino)-3-methyl-guanidine is obtained in the form of a dihydrochloride.

B) SYNTHESIS OF SUBSTITUTED CEPHALOSPORINES**20 a) 3-[(E)[[1-(3-(aminobenzylamino)-iminomethyl]-methylhydrazono] methyl]-7-[[[(5-amino-[1,2,4]thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino]-3-cephem-4-carboxylic acid trihydrochloride**

To a mixture of 2 g of 3-amino-1-(aminobenzylamino)-3-methyl-guanidine in the form of a dihydrochloride in 3.4 ml of 2M HCl and 6.1 ml of dimethylacetamide, 2.78 g of N-(1,4,5a,6-
 25 tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto(2,1-b)furo(3,4-d)(1,3)-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino) acetic acid amide are added and the suspension obtained is stirred at RT. The mixture obtained is poured into acetonitrile under stirring. A precipitate formed is filtrated off, washed and dried. 3-[(E)[[1-(3-(aminobenzylamino)-iminomethyl]-methylhydrazono] methyl]-7-[[[(5-amino-[1,2,4]thiadiazol-3-
 30 yl)-(Z)-(fluoromethoxyimino)-acetyl] amino]-3-cephem-4-carboxylic acid is obtained in the form of a trihydrochloride.

- 8 -

**b) 3-{(E)[[1-(3-(aminobenzylamino)-iminomethyl)-methylhydrazono] methyl}-7-
methyl}-7-{[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]
amino}-3-cephem-4-carboxylic acid monohydrochloride**


10 g of the crude 3-{(E)[[1-(3-(aminobenzylamino)-iminomethyl)-methylhydrazono] methyl}-7-
5 {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino}-3-cephem-4-
carboxylic acid in the form of a trihydrochloride are dissolved in 42 ml of water and subjected
to chromatography (e.g. LiChroprep RP-18^R, Merck, grain size 40-63 μ m). Fractions
containing the desired compound in the form of a monohydrochloride (HPLC determination)
are combined and lyophilised and 3-{(E)[[1-(3-(aminobenzylamino)-iminomethyl)-
10 methylhydrazono]methyl}-7-{[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]
amino}-3-cephem-4-carboxylic acid is obtained in the form of a monohydrochloride.

¹H-NMR (200 MHz, DMSO-d₆)

3.38, s, 3H, NCH₃; 3.52, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 4.50 – 4.75, m, 3H, 2H
from NCH₂ and 1H from SCH₂; 5.29, d, J=5 Hz, 1H, β -lactam; 5.76, d, J=55 Hz, 2H, CH₂F;
15 5.95, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 7.25 – 7.60, m, 4H, aromatic H; 8.17, s, 1H,
CH=N; 9.75, d, J=8 Hz, 1H, NH

Patent claims

1. A compound of formula



5

wherein

W is CH or N,

R₁ is hydrogen or O-R₁'

10 R₁' is hydrogen, (C₁₋₆)alkyl, halo(C₁₋₆)alkyl or hydroxycarbonyl(C₁₋₆)alkyl,

R₂ is hydrogen or an ester moiety,

R₃ is hydrogen, (C₁₋₂)alkyl, allyl or (C₃₋₈)cycloalkyl,

R₄ is hydrogen or (C₁₋₂)alkyl,

15 R₅ and R₆ independently of each other are hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl-carbonyloxy, arylcarbonyloxy, (C₁₋₆)alkylsulfonyl or arylsulfonyl, and

X = NH, O or S.

2. A compound of claim 1, wherein

R₁ is fluoromethyl

20 R₂, R₄, R₅ and R₆ are hydrogen,

R₃ is methyl,

X = NH, and

N-R₅R₆ is in m position.

25 3. A compound of claim 1 or 2 in the form of a salt.

4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 in association with at least one pharmaceutical excipient.

30 5. A compound according to any one of claims 1 to 3 for use as a pharmaceutical.

- 10 -


6. A compound according to claim 5 for the treatment of microbial diseases.

5 7. A method of treatment of microbial diseases which comprises administering to a subject in
need of such treatment an effective amount of a compound according to any one of
claims 1 and 4.

IL/14-Oct-2002

Abstract

A compound of formula



wherein the substituents have various meanings, useful as a pharmaceutical.